Renerve (ASX:RNV)
ASX announcement history & article coverage
Transparent by design.
Announcments by Renerve (ASX:RNV) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Positive 12-Month Data for NervAlign Nerve Guide Matrix
ReNerve reports positive 12-month sheep data for 4cm nerve repair implant
Positive FDA Feedback on NervAlign Nerve Guide Matrix
ReNerve receives positive FDA feedback for NervAlign Nerve Guide Matrix pathway
Change of Director's Interest Notice - P Savage
Change of Director's Interest Notice - M McGuire
Change of Director's Interest Notice - J Chick
Cleansing Notice
Application for quotation of securities - RNV
Proposed issue of securities - RNV
Notification regarding unquoted securities - RNV
Results of Meeting
ReNerve AGM Presentation
ReNerve reports 88% annual revenue growth and advances nerve repair pipeline
ReNerve completes first cases in Hong Kong and Malaysia
ReNerve begins commercial NervAlign sales in Hong Kong and Malaysia as FY26 revenue rises 88%
Change in substantial holding - J Chick
Change of Director's Interest Notice - J Chick
ReNerve and RMIT awarded $499k grant
ReNerve and RMIT awarded $499k grant for nerve regeneration project targeting prostate surgery recovery
Notice of Annual General Meeting/Proxy Form
ReNerve - Corporate Governance Statement
ReNerve - Appendix 4G
ReNerve - Full Year Results
ReNerve Reports Record FY26 Sales Growth and Expands Global Market Access
ReNerve - 2026 Annual Report
ReNerve reports 88% revenue growth, expands Asia-Pacific approvals, advances nerve repair pipeline, and secures $5 million funding facility
ReNerve - Appendix 4E
ReNerve Limited reports increased loss and lower net tangible assets for FY2026
Cleansing Notice
Application for quotation of securities - RNV
Proposed issue of securities - RNV
Quarterly Investor Presentation
ReNerve reports strong revenue growth and advances nerve repair product pipeline with global expansion
Quarterly Investor Webinar
ReNerve Secures Marketing Approval in India
ReNerve Secures Indian Marketing Approval for NervAlign® Nerve Cuff
ReNerve Secures Marketing Approval in the Philippines
ReNerve gains marketing approval for NervAlign® Nerve Cuff in the Philippines, expanding Asia-Pacific footprint
Change of Director's Interest Notice - J Chick
Q4 FY26 Activities Report and Appendix 4C
ReNerve reports record sales, Asia-Pacific expansion, and $5M funding facility
